Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CSTL
STRONG SELLCastle Biosciences, Inc. · Healthcare · United States · $749M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Castle Biosciences, Inc. is a commercial-stage dermatological diagnostics company focused on improving patient care through its proprietary genomic tests for skin cancers. The company's tests provide actionable information to clinicians and patients to guide treatment decisions and predict recurrence risk for melanoma, cutaneous squamous cell carcinoma, and other dermatologic conditions. Castle Biosciences holds a niche leadership position by developing and commercializing clinically validated molecular diagnostics for challenging dermatologic cancers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 137.0M | 219.8M | 332.1M | 344.2M | 35.9% | 339.9M | 352.3M | 392.9M | 6.8% |
| EPS | -2.58 | -2.14 | 0.66 | -0.83 | — | -0.42 | -1.42 | -0.96 | — |
| Shares | 26.6M | 27.4M | 28.5M | 29.7M | +11.8% | 30.3M | — | — | — |
| Debt | 13.4M | 15.3M | 26.3M | 36.9M | 40.2% | 36.7M | — | — | — |
| Equity | 399.1M | 391.3M | 455.8M | 470.9M | 5.7% | — | — | — | — |
| Op CF | -41.7M | -5.6M | 64.9M | 64.3M | -0.8% | 48.3M | — | — | — |
| Inv CF | -166.5M | -16.2M | -50.1M | -60.4M | — | — | — | — | — |
| Fin CF | 1.5M | -2.3M | 6.1M | -7.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CSTL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CSTL | Castle Biosciences, Inc.(you) | $749M | 19 | STRONG SELL |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| FRNM | Freenome, Inc. | $1.2B | 11 | STRONG SELL |
| OPK | OPKO Health, Inc. | $921M | 35 | HOLD |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
| MYGN | Myriad Genetics, Inc. | $530M | 35 | SELL |
| GRAL | GRAIL, Inc. | $2.9B | 19 | STRONG SELL |
| XGN | Exagen Inc. | $113M | 17 | STRONG SELL |
| BDSX | Biodesix, Inc. | $228M | 38 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%